UCB Stock Other OTC
Stocks
UCBJF
BE0003739530
Pharmaceuticals
OTC Markets Traded| Market Cap | 41.07B 47.57B 38.53B 35.09B 65.99B 4,548B 66.9B 452B 177B 2,279B 179B 175B 7,580B | P/E 2026 * |
21.6x | P/E 2027 * | 17.7x |
|---|---|---|---|---|---|
| Enterprise Value | 41.39B 47.94B 38.83B 35.37B 66.5B 4,584B 67.42B 455B 178B 2,297B 180B 176B 7,640B | EV / Sales 2026 * |
4.76x | EV / Sales 2027 * | 4.05x |
| Free-Float |
61.59% | Yield 2026 * |
0.68% | Yield 2027 * | 0.7% |
Last Transcript: UCB
| 1 day | -0.39% |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 67 | 2014-12-31 | |
Sandrine Dufour
DFI | Director of Finance/CFO | 60 | 2020-06-30 |
Alistair Henry
CTO | Chief Tech/Sci/R&D Officer | 59 | 2024-04-30 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 55 | 2011-12-31 | |
| Director/Board Member | 67 | 2014-12-31 | |
| Director/Board Member | 56 | 2014-04-23 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.39% | -.--% | - | - | 47.57B | |
| +0.30% | -0.26% | +38.86% | +1.15% | 80.48B | |
| -1.02% | -1.34% | -2.54% | +30.42% | 50.63B | |
| -0.37% | -5.13% | +9.80% | +166.58% | 47.57B | |
| +17.25% | +14.09% | -41.83% | -41.67% | 45.84B | |
| -0.32% | +0.98% | +50.90% | -20.02% | 30.9B | |
| +1.80% | +7.77% | +130.05% | -39.33% | 25.73B | |
| +2.78% | +1.60% | +42.08% | +92.34% | 25.03B | |
| +1.36% | +1.15% | -5.15% | +207.31% | 21.16B | |
| +1.09% | +4.76% | +64.56% | +126.22% | 16.75B | |
| Average | +1.90% | +0.46% | +31.86% | +58.11% | 38.23B | |
| Weighted average by Cap. | +2.02% | -0.10% | +24.68% | +43.09% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 8.69B 10.06B 8.15B 7.42B 13.96B 962B 14.15B 95.55B 37.44B 482B 37.78B 36.97B 1,604B | 9.69B 11.22B 9.09B 8.28B 15.57B 1,073B 15.78B 107B 41.76B 538B 42.14B 41.23B 1,789B |
| Net income | 1.93B 2.23B 1.81B 1.65B 3.09B 213B 3.14B 21.17B 8.3B 107B 8.37B 8.19B 355B | 2.33B 2.7B 2.18B 1.99B 3.74B 258B 3.79B 25.6B 10.03B 129B 10.12B 9.9B 430B |
| Net Debt | 321M 372M 301M 274M 516M 35.57B 523M 3.53B 1.38B 17.82B 1.4B 1.37B 59.29B | -1.8B -2.08B -1.69B -1.54B -2.89B -199B -2.93B -19.78B -7.75B -99.8B -7.82B -7.65B -332B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
